Novo Nordisk Foundation Expands Carb-X Funding for Antimicrobial Resistance Products

MT Newswires · 2d ago
01:42 AM EST, 11/18/2026 (MT Newswires) -- Novo Nordisk Foundation committed $60 million in funding to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, or Carb-X, to advance the development of products for bacterial infections and antimicrobial resistance. The four-year funding builds on an initial $25 million grant provided to the non-profit public-private partnership in 2024, according to a Wednesday release. Novo Nordisk Foundation owns Novo Holdings, the controlling shareholder of drugmaker Novo Nordisk (NOVO-B.CO).